151. IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance.
- Author
-
Singh KS, Sharma R, Reddy PAN, Vonteddu P, Good M, Sundarrajan A, Choi H, Muthumani K, Kossenkov A, Goldman AR, Tang HY, Totrov M, Cassel J, Murphy ME, Somasundaram R, Herlyn M, Salvino JM, and Dotiwala F
- Subjects
- Animals, Drug Resistance, Microbial, Drug Resistance, Multiple, Enzyme Inhibitors chemistry, Escherichia coli Proteins genetics, Escherichia coli Proteins metabolism, Female, Half-Life, Humans, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear microbiology, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Microbial Sensitivity Tests, Molecular Docking Simulation, Oxidoreductases deficiency, Oxidoreductases genetics, Oxidoreductases metabolism, Prodrugs pharmacokinetics, Prodrugs pharmacology, Substrate Specificity, Swine blood, T-Lymphocytes, Cytotoxic immunology, Drug Design, Enzyme Inhibitors pharmacology, Escherichia coli Proteins antagonists & inhibitors, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria immunology, Lymphocyte Activation drug effects, Microbial Viability drug effects, Oxidoreductases antagonists & inhibitors, T-Lymphocytes, Cytotoxic drug effects
- Abstract
Isoprenoids are vital for all organisms, in which they maintain membrane stability and support core functions such as respiration
1 . IspH, an enzyme in the methyl erythritol phosphate pathway of isoprenoid synthesis, is essential for Gram-negative bacteria, mycobacteria and apicomplexans2,3 . Its substrate, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), is not produced in metazoans, and in humans and other primates it activates cytotoxic Vγ9Vδ2 T cells at extremely low concentrations4-6 . Here we describe a class of IspH inhibitors and refine their potency to nanomolar levels through structure-guided analogue design. After modification of these compounds into prodrugs for delivery into bacteria, we show that they kill clinical isolates of several multidrug-resistant bacteria-including those from the genera Acinetobacter, Pseudomonas, Klebsiella, Enterobacter, Vibrio, Shigella, Salmonella, Yersinia, Mycobacterium and Bacillus-yet are relatively non-toxic to mammalian cells. Proteomic analysis reveals that bacteria treated with these prodrugs resemble those after conditional IspH knockdown. Notably, these prodrugs also induce the expansion and activation of human Vγ9Vδ2 T cells in a humanized mouse model of bacterial infection. The prodrugs we describe here synergize the direct killing of bacteria with a simultaneous rapid immune response by cytotoxic γδ T cells, which may limit the increase of antibiotic-resistant bacterial populations.- Published
- 2021
- Full Text
- View/download PDF